Personal Care Products

Runben Biotechnology

Runben Biotechnology released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 267.09 M, actual EPS CNY 0.13

Runben Biotechnology released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 307.27 M, actual EPS CNY 0.12

Runben Biotechnology released FY2025 earnings on April 22 After-Market (BJT), actual revenue CNY 1.545 B (forecast CNY 1.58 B), actual EPS CNY 0.78 (forecast CNY 0.8333)

Runben Biotechnology to Release FY2026 Q1 Earnings on April 23 After-Market (BJT)

Runben Biotechnology to Release FY2025 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 1.58 B, EPS CNY 0.8333

Runben Biotechnology released FY2025 9 Months earnings on October 20 After-Market (BJT), actual revenue CNY 1.238 B, actual EPS CNY 0.6558

Runben Biotechnology released FY2025 Q3 earnings on October 20 After-Market (BJT), actual revenue CNY 342.41 M, actual EPS CNY 0.1993

Runben Biotechnology FY2025 Q3 Earnings Release on October 21, 2025 After-Market (BJT)

Runben Biotechnology released FY2025 Semi-Annual Earnings on August 18 After-Market (BJT), actual revenue CNY 895.11 M, actual EPS CNY 0.46

Runben Biotechnology released FY2025 Q2 earnings on August 18 After-Market (BJT), actual revenue CNY 655.08 M, actual EPS CNY 0.3465

Runben Biotechnology to Release FY2025 Semi-Annual Earnings on August 19, 2025 (BJT)

Chikungunya Outbreak in Guangdong May Boost Runben's Mosquito Repellent Sales

Citic Securities Analyst Releases Buy Rating Report on Runben Stock

Riben Stock's Shareholder Sells 1,585,500 Shares

Riben Shares Surpass 1.6B Yuan in Market Cap, Become a Leading Cosmetics Player

Riben Shares Acquires New Land for Biotech R&D Base Construction

Riben Shares Rise and Receive Buy Rating

Southwest Securities Gives Buy Rating to Runben Shares

Ping An Securities Releases FY2024 Financial Report Analysis for Runben Shares

Riben Shares Reports Q1 2025 Revenue and Net Profit Growth

603193

According to the Zhitong Finance APP, Runben Biotechnology disclosed its third-quarter report for 2025. The company achieved revenue of 1.238 billion yuan in the first three quarters, a year-on-year increase of 19.28%; the net profit attributable to shareholders of the listed company was 266 million yuan, a year-on-year increase of 1.98%; the net profit excluding non-recurring gains and losses was 251 million yuan, a year-on-year decrease of 1.79%; the basic earnings per share were 0.66 yuan

Zhitong

Runben Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 266 million yuan, a year-on-year increase of 1.98%

Runben Biotechnology Co., Ltd. announced the distribution of equity for the first half of 2025, with a cash dividend of RMB 0.20 per share, totaling RMB 80,918,662.80. The equity registration date is September 17, and the ex-dividend date and cash dividend payment date is September 18. Individual shareholders holding shares for more than one year may be temporarily exempt from individual income tax, and the reduction price for some shareholders is adjusted to no less than RMB 16.60 per share. Shareholders can contact the securities department for inquiries

Runben Biotechnology 2025 Half-Year Equity Distribution: Cash Dividend of 0.2 Yuan per Share

Runben Biotechnology released its semi-annual report for 2025, with operating revenue of 895 million yuan, a year-on-year increase of 20.31%; net profit attributable to the parent company of 188 million yuan, a year-on-year increase of 4.16%. The net profit excluding non-recurring gains and losses was 177 million yuan, a year-on-year increase of 0.86%. The basic earnings per share were 0.46 yuan. The company launched more sunscreen products, expanded offline channels, and plans to distribute a cash dividend of 2.00 yuan for every 10 shares to all shareholders

Runben Biotechnology released its performance for the first half of the year, with a net profit attributable to the parent company of 188 million yuan, an increase of 4.16%

688157

This week's largest increase in margin financing balance: Runben Biotechnology margin financing balance: 326 million yuan, balance increase: 147.62%; SOKAN margin financing balance: 125 million yuan, balance increase: 103.81%

SOKAN

09863

As global markets face rising consumer inflation and strong corporate earnings, indices like the S&P 500 and Nasdaq Composite have reached new highs. Growth companies with high insider ownership are noteworthy for their innovation potential and alignment of interests. The top 10 companies include Zhejiang Leapmotor Technology, Shanghai Huace Navigation Technology, and Runben Biotechnology, all showing promising revenue growth forecasts. However, some companies, like ASE Technology Holding, face challenges with dividend coverage and stock valuation. This analysis highlights opportunities in the current market landscape.

Simplywall

LEAPMOTOR

Global Growth Companies With High Insider Ownership To Watch

300886

603630

301009

300955

600315

The beauty and personal care sector is rising, with Runben Biotechnology hitting the daily limit, JAHEN rising over 10%, and Shanghai Jahwa, Hyea Aromas, Lafang, BAWI, Coco Healthcare, and others following suit

Hyea Aromas

Lafang

Coco Healthcare

JAHEN

Shanghai Jahwa

The beauty and personal care sector rises, Runben Biotechnology hits the limit up

Runben Biotechnology plans to invest 600 million yuan in the International Biomedical Innovation Park of the Guangzhou Knowledge City in Huangpu District, Guangzhou, to build a biotechnology R&D and production base project. The project will include office areas, R&D areas, living areas, and production manufacturing areas, aiming to meet the R&D and production needs of the personal care products, cosmetics, medical devices, and pharmaceutical manufacturing industries. This move will further consolidate the company's C2M supply chain barriers and support future growth in production, sales, and research

Runben Biotechnology: Plans to invest 600 million yuan to build a Runben biotechnology research and production base project

300548

Three global growth companies with high insider ownership are expected to see significant revenue growth: Runben Biotechnology (29.6% insider ownership, 23% revenue growth forecast), Wuhan Guide Infrared (27.1% insider ownership, 27.6% revenue growth forecast), and Broadex Technologies (11.5% insider ownership, 21.6% revenue growth forecast). These companies are positioned to outperform the broader market amid improving economic conditions and are attracting investor interest due to management's confidence in their business trajectories.

EverProX

3 Global Growth Companies With High Insider Ownership Expecting Up To 27% Revenue Growth

According to the Zhitong Finance APP, Runben Biotechnology disclosed its first-quarter report for 2025, showing that the company achieved revenue of 240 million yuan during the reporting period, a year-on-year increase of 44%; net profit attributable to the parent company was 44.2 million yuan, a year-on-year increase of 24.60%; and net profit excluding non-recurring gains and losses was 38.62 million yuan, a year-on-year increase of 22.85%. Basic earnings per share were 0.11 yuan

Runben Biotechnology released its first-quarter performance, with a net profit attributable to the parent company of 44.2 million yuan, a year-on-year increase of 24.60%

Runben Biotechnology announced that shareholder JNRY VIII will reduce its holdings by 2.0229 million shares from April 10 to April 15, 2025, bringing its shareholding ratio down to 5%. After the reduction, JNRY VIII's holdings will decrease from 22.2526 million shares to 20.2297 million shares, and it will no longer be a shareholder with more than 5% ownership

Runben Biotechnology: JNRY VIII's shareholding ratio has decreased to 5%

Runben Biotechnology(603193.SH)